Companies · Biotechnology

Ocean Biomedical, Inc.

PROVIDENCE · Biotechnology

Diligence memoA one-page analyst read on Ocean Biomedical, Inc. — recommendation, valuation, rhythm, risks.
$8.6M
Total raised · real
2
Rounds
7.2×
Latest step-up
Top 48%
Sector rank · raised
Series A
Latest stage · inferred · Thu May 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Ocean Biomedical, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.52× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
  • Issuer reports no revenue, yet is modeled well above niche peers.
At-risk
  • Last raise 3.1 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Ocean Biomedical, Inc. is one of 4291 Biotechnology companies tracked from PROVIDENCE. By capital raised it ranks mid-pack (ahead of 53% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
1
Investors (latest)
2021
Year incorporated
2023-05-25
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2021-03-22 Raised $1.0M (real) Modeled valuation $31M (est)$1.0M$31MSeed2021Series A · 2023-05-25 Raised $7.6M (real) Modeled valuation $68M (est)$7.6M$68MSeries A2023+$7.6MCumulative $8.6M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.0M · 2021
Series A$7.6M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$67.5M
Base estimate est.
$8.2M
Conservative case
$188.2M
Upside case
$34.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $31.1M · 2021-03-222021Series A · modeled $67.5M · 2023-05-252023
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
3.1 yr
Elapsed time used
3.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
26 mo
Avg between rounds
$4.0M/yr
Capital velocity
5.3 yr
On record since
2021
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.2× above median
This company$8.6M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.4× above median
This company$7.6M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 1.1× above median
This company$67.5M
Sector median$64.2M

Raised more than 53% of sector peers (real $). Modeled value above 51% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #100 of 303.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.0M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $215.9M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $206.8M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.3M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $188.9M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.0M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.7M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $183.8M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.2M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.2M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.1M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $168.8M (est)Ocean Biomedical, Inc. (this company) Raised $8.6M · modeled $67.5M (est)Ocean Biomedical, Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.0M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$215.9M4.87×
Adient Medical, Inc.Series A$18.2M$206.8M4.67×
Entegrion IncSeries A$22.7M$191.3M4.32×
BCD Bioscience, Inc.Series A$16.4M$188.9M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.0M4.20×
MicroByre, Inc.Series A$16.1M$185.7M4.19×
Cardiac Insight, Inc.Series A$38.1M$183.8M4.15×
Cardiac Implants LLCSeries A$13.5M$178.2M4.02×
Abintus Bio, Inc.Series A$13.7M$177.2M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.1M3.98×
Mazen Animal Health Inc.Series A$13.5M$168.8M3.81×
Ocean Biomedical, Inc. this companySeries A$8.6M$67.5M1.52×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.0M2021-03-22$5.2M$31.1M90%
Series A$7.6M2023-05-25$34.4M$67.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.0M2021-03-22
    • First recorded raise — entered as Seed.
    • 27 investors on this round.
  2. Series A$7.6M2023-05-25
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 7.2× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2025 ~Q3
Modeled next raise · ~26mo cadence
$22.7M
Modeled next size est.range $14.7M$36.3M
7.2×
Last step-up
$4.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
William A Owens5 other2023-05
Daniel Behr3 other2023-05
MICHAEL A PETERSON2 other2023-05
Jonathan Heller1 other2021-03
Robert Sweeney1 other2023-05
Chirinjeev Kathuria,2021-03
Elizabeth Ng2021-03
Gurinder Kalra2021-03
Inderjote Kathuria2023-05
Jack A. Elias2023-05
Jerome A. Ringo2023-05
Jonathan A. Kurtis2023-05
Martin D. Angle2023-05
Michelle D. Berrey2023-05
Suren A. Ajjarapu2023-05
Registry & provenance

Ocean Biomedical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1869974
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
eXIthera Pharmaceuticals, Inc.BiotechnologySeries A$15.0M$108.5Mnetwork1 shared operator · same sector · same stage
Mnemosyne Pharmaceuticals IncBiotechnologySeries A$24.0M$445.8Mnetwork1 shared operator · same sector · same stage
Islet Sciences, IncBiotechnologySeries A$8.5M$80.3Msame sector · same stage
AbbraTech Holdings LLCBiotechnologySeries A$8.5M$59.4Msame sector · same stage
Immune Therapeutics, Inc.BiotechnologySeries A$8.5M$63.5Msame sector · same stage
CohBar, Inc.BiotechnologySeries A$8.7M$77.5Msame sector · same stage
Regen Biologics IncBiotechnologySeries A$8.8M$61.5Msame sector · same stage
Simergent, LLCBiotechnologySeries A$8.8M$52.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Shoreline Biosciences, Inc.BiotechnologySeries D+$3.7B89%
Aqua Medical LlcBiotechnologyPre-Seed$11.3M88%
CytoBioscience, Inc.BiotechnologySeries B$60.7M88%
Gulf Sterilization, Inc.BiotechnologyPre-Seed$337K88%
Island Pharmaceuticals LtdBiotechnologySeed$7.1M87%
Jupiter Biomedical Research, Inc.BiotechnologyPre-Seed$843K87%
Aquaro Histology, Inc.BiotechnologySeries A$354.7M87%
Vista Biomedical, Inc.BiotechnologyPre-Seed$3.0M87%
Frequently asked
How much funding has Ocean Biomedical, Inc. raised?
Ocean Biomedical, Inc. has raised approximately $8.6M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Ocean Biomedical, Inc.'s estimated valuation?
Provath's modeled valuation for Ocean Biomedical, Inc. is approximately $67.5M (modeled range $8.2M–$188.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Ocean Biomedical, Inc. at?
Ocean Biomedical, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu May 25.
What does Ocean Biomedical, Inc. do and where is it based?
Ocean Biomedical, Inc. operates in the Biotechnology sector, based in PROVIDENCE.
Explore related

See where Ocean Biomedical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Ocean Biomedical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.